BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu J, Zhu J, Wei Q. Adjuvant Radiochemotherapy vs Chemotherapy Alone for Gastric Cancer: Implications for Target Definition. J Cancer. 2019;10:458-466. [PMID: 30719140 DOI: 10.7150/jca.27335] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ramos MFKP, Pereira MA, Cardili L, de Mello ES, Ribeiro Jr U, Zilberstein B, Cecconello I. Expression profiles of gastric cancer molecular subtypes in remnant tumors. World J Gastrointest Oncol 2021; 13(4): 265-278 [PMID: 33889278 DOI: 10.4251/wjgo.v13.i4.265] [Reference Citation Analysis]
2 Liu AG, Zhong JC, Chen G, He RQ, He YQ, Ma J, Yang LH, Wu XJ, Huang JT, Li JJ, Mo WJ, Qin XG. Upregulated expression of SAC3D1 is associated with progression in gastric cancer. Int J Oncol 2020;57:122-38. [PMID: 32319600 DOI: 10.3892/ijo.2020.5048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Shin IS, Rim CH. Stepwise-Hierarchical Pooled Analysis for Synergistic Interpretation of Meta-analyses Involving Randomized and Observational Studies: Methodology Development. J Med Internet Res 2021;23:e29642. [PMID: 34315697 DOI: 10.2196/29642] [Reference Citation Analysis]
4 Shen J, Zhu X, Du Y, Zhu Y, Yu P, Yang L, Xu Z, Huang L, Zhang Y, Zhang Y, Liu L, Cheng X. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG). Trials 2021;22:753. [PMID: 34717717 DOI: 10.1186/s13063-021-05617-7] [Reference Citation Analysis]
5 Xu J, Shen L, Shui Y, Yu W, Guo Q, Yu R, Wu Y, Wei Q. Patterns of recurrence after curative D2 resection for gastric cancer: Implications for postoperative radiotherapy. Cancer Med 2020;9:4724-35. [PMID: 32420703 DOI: 10.1002/cam4.3085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Andreollo NA, Drizlionoks E, Tercioti-Junior V, Coelho-Neto JS, Ferrer JAP, Carvalheira JBC, Lopes LR. ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER? Arq Bras Cir Dig 2019;32:e1464. [PMID: 31859917 DOI: 10.1590/0102-672020190001e1464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]